RQM+ Acquires Jordi Labs

“As the only MedTech service provider rooted in almost 40 years of regulatory strategy, RQM+ is proud to now offer proprietary testing services for extractables and leachables, which gives our customers the fastest path to regulatory approvals,” said CEO Margaret Keegan. “

RQM+, the leading MedTech service provider with the world’s largest global team of regulatory and quality experts, and portfolio company of Linden Capital Partners, today announced the acquisition of Jordi Labs. With these new capabilities, RQM+ provides comprehensive regulatory, quality, clinical and laboratory services, supporting market access throughout the entire product lifecycle for medical devices and diagnostics.

“As the only MedTech service provider rooted in almost 40 years of regulatory strategy, RQM+ is proud to now offer proprietary testing services for extractables and leachables, which gives our customers the fastest path to regulatory approvals,” said CEO Margaret Keegan. “We are relentlessly focused on being the best at every service we provide to MedTech manufacturers. Jordi’s world-leading testing services will help us maintain our uncompromising quality standards at every stage as we grow into a one-stop-shop to expedite patient access to life-improving technologies.”

Through innovative new processes, Jordi Labs provides chemical characterization and complex product deformulation as well as contaminant and failure investigations to MedTech manufacturers. Their team of Ph.D. analytical chemists uses its proprietary, multi-detector approach to ensure that all extractables are accurately characterized to comply with global materials testing regulatory requirements. Jordi’s publications based on their multi-detector approach are frequently cited by both regulators and industry.

“We are delighted to now be a part of the RQM+ solution that brings customers to market faster with our unmatched track record of rapid testing results that satisfy the stringent requirements of regulators globally,” said Mark Jordi, president of Jordi Labs. “Joining RQM+ will enable me to focus on what I love – developing groundbreaking technology that ensures patient safety by setting new standards for extractables and leachables testing.”

Kirkland and Ellis LLP served as legal advisor to Linden. Harris Williams represented Jordi Labs.

More

Artificial Intelligence Tools Make Education Materials More Patient Friendly

April 30, 2025

“Our study shows that widely used large language models have the potential to transform patient education materials into more readable content, which is essential for patient empowerment and better health outcomes,” said Study senior author Jonah Feldman, MD, medical director of transformation and informatics at NYU Langone.

CorWave Completes 6-Month In Vivo Study for Clinical Trials Initiation

April 24, 2025

In vivo studies demonstrated the pump’s successful operation for a period of up to six months. Additionally, nine chronic ovine implants were conducted for 60 days with no device failure or sign of thrombosis at explant. These significant milestones mark the final stage of CorWave’s preclinical development, paving the way for its First-In-Human study.